INNOVATION FOR PATIENTS

Advancing drug discovery & development through embedded collaborations and integrated service partnerships.

ABOUT US

img

Aniesis is a biotechnology company focused on expanding healthcare access in underserved regions. With over 80 years of combined life science experience, our team has advanced preclinical candidates to first in human trials, delivering impact for partners and patients alike. We address healthcare gaps across Africa, South Asia, Southeast Asia, Latin America, Central Asia, parts of the Middle East, and Pacific Island nations, bringing next generation therapies to communities where infrastructure and R&D capacity are limited. Through precision biology, AI driven screening, and real world data, we tailor drug discovery to local needs. Our alliances with academic, nonprofit, and industry leaders power an end to end innovation ecosystem, from target identification to in vivo validation. Aniesis’s modular R&D campus provides integrated services including screening, lead optimization, pharmacokinetics, and safety, designed to move medicines faster to where they're needed most.

COLLABORATIVE DRUG DISCOVERY

Aniesis is committed to bringing innovative therapies to patients, leveraging our expertise and experience through:

GLOBAL PARTNERSHIP AND ALLIANCES

  • Working with global partners to discover and advance preclinical R&D assets for improved patient outcomes.
  • Embedded relationships with different collaborative models, tailored for each project and partner.

PLATFORM TECHNOLOGIES ACROSS DIVERSE THERAPEUTIC AREAS

  • Proprietary platform technologies to accelerate, enable and repurpose drugs and novel therapeutics.
  • Therapeutic area expertise spanning oncology, metabolic disorders, CNS, mitochondrial dysfunction and rare genetic disorders.

FOCUS ON RARE AND NEGLECTED DISEASES

  • Integrated infrastructure, with therapeutic agnostic experience and the agility of a small biotech makes Aniesis ideally suited to tackle rare and neglected diseases.
  • Using repurposing to create a viable strategy for addressing rare diseases.

INTEGRATED DRUG DISCOVERY SERVICES

image
icon

CHEMISTRY

  • NCE design and synthesis, Hit-to-lead and lead optimization.
  • Library design and synthesis - various scaffolds like heterocycles, steroids, PROTAC, etc supported by complete Analytical capabilities.
image
icon

IN-VITRO PHARMACOLOGY

  • Assay development for enzymatic and cell- based screening.
  • Biomarker validation & profiling
  • IN-VITRO ADME Profiling studies
image
icon

IN-VIVO PHARMACOLOGY

  • Range of in VIVO pre-clinical efficacy, pharmacology, and safety models across diverse therapeutic applications
  • Development of complex, disease specific IN-VIVO models
  • Pharmacokinetic Studies in rodents

TEAM